Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a&nbsp;meta-analysis

Lampertico, Pietro; Carrión, Jose A; Curry, Michael; Turnes, Juan; Cornberg, Markus; Negro, Francesco; Brown, Ashley; Persico, Marcello; Wick, Nicole; Porcalla, Ariel; Pangerl, Andreas; Crown, Eric; Larsen, Lois; Yu, Yao; Wedemeyer, Heiner

doi:10.1016/j.jhep.2020.01.025

Scientific article

English

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis

ContributorsLampertico, Pietro; Carrión, Jose A; Curry, Michael; Turnes, Juan; Cornberg, Markus; Negro, Francesco; Brown, Ashley; Persico, Marcello; Wick, Nicole; Porcalla, Ariel; Pangerl, Andreas; Crown, Eric; Larsen, Lois; Yu, Yao; Wedemeyer, Heiner

Published inJournal of Hepatology, vol. 72, no. 6, p. 1112-1121

Publication date2020

Abstract

Glecaprevir/pibrentasvir is approved for treating adults infected with HCV genotypes 1-6. In clinical trials, glecaprevir/pibrentasvir was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12) and was well tolerated. A systematic review and meta-analysis of the real-world effectiveness and safety of glecaprevir/pibrentasvir were undertaken.

Affiliation entities

Research groups

Etudes et traitement de l'hépatite C et B (554)

Citation (ISO format)

LAMPERTICO, Pietro et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis. In: Journal of Hepatology, 2020, vol. 72, n° 6, p. 1112–1121. doi: 10.1016/j.jhep.2020.01.025

Article (Published version)

CC BY-NC-ND

Identifiers

PID : unige:144120
DOI : 10.1016/j.jhep.2020.01.025
PMID : 32061651

ISSN of the journal0168-8278

197views

127downloads

Creation16/10/2020 15:02:00

First validation16/10/2020 15:02:00

Update time15/03/2023 22:57:01

Status update15/03/2023 22:57:00

Last indexation02/10/2024 10:38:05

Archive ouverte UNIGE

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis

Technical informations